Overview of Arcus Biosciences#

Mizuho has reaffirmed an Outperform rating for Arcus Biosciences (NYSE:RCUS) after the company announced the discontinuation of its Phase 3 trial, STAR-121. Currently, the stock is trading at $22.45, which represents a significant 208% increase over the past year, although it has seen a 5% decline from the previous close.

Trial Discontinuation Details#

The Phase 3 trial aimed to evaluate the effectiveness of domvanalimab combined with zimberelimab and chemotherapy in treating non-small cell lung cancer. However, following a futility analysis—an assessment indicating that the trial is unlikely to succeed—the trial has been halted. Additionally, Arcus disclosed that Gilead Sciences’ option rights to earlier pipeline assets will expire on July 14, 2026, due to a missed payment.

Focus on Future Research#

Mizuho noted that these developments were anticipated and that Arcus can now redirect its research and development efforts towards casdatifan, a treatment for clear cell renal cell carcinoma. The firm indicated that prior to this announcement, domvanalimab had little value in the stock, especially after previous trial discontinuations. Arcus Biosciences, valued at $2.85 billion, maintains a healthy financial position with more cash than debt, according to analysis.

Upcoming Developments#

Arcus is set to release data from multiple early studies involving casdatifan, including its combination with zimberelimab for treating clear cell renal cell carcinoma. Mizuho estimates that casdatifan could generate around $5.5 billion in peak sales globally. The company plans to initiate a Phase 3 trial for this treatment by the end of 2026. In its recent earnings report, Arcus exceeded earnings per share expectations but fell short on revenue, posting an EPS of -$0.89 against a projected -$1.1, and revenue of $33 million compared to an expected $35.71 million. Additionally, the company announced the resignation of its Chief Operating Officer, Jennifer Jarrett, effective March 30, who will continue to provide advisory services until June 30.